Abstract
A direct test for activated platelets in whole blood was developed by radioimmunoassay with {sup 125}I labeled SZ-51, an antibody specific for an {alpha}-granule membrane protein (GMP-140) that associates with the platelet surface during secretion. The assay had sufficient sensitivity to detect as few as 2% activated platelets. In 50 normal subjects, minimal GMP-140 molecules per platelet were expressed on the surface of circulating platelets. Ten patients undergoing cardiopulmonary bypass had transiently increased expression of GMP-140 molecules during the bypass procedure, especially at the end of bypass. Evaluation of 18 patients with epidemic hemorrhagic fever (EHF) has shown that the number of GMP-140 molecules on the platelet surface was closely related to the four different phases of EHF. In six patients suffered from acute myocardial infarction (AMI), the number of GMP-140 molecules changed with the procession of AMI and the highest occurred 48 h after AMI. The GMP-140 molecules were also increased in patients with asthma attack (n = 14), but not in patients with idiopathic thrombocytopenic purpura (n = 11) and diabetic mellitus (n = 48). Taken together, these studies suggest that activated platelet can be reliably measured in whole blood using radiolabeled SZ-51 antibody and the detection of
More>>
Citation Formats
Guoxin, Wu, Fugang, Li, Jianyong, Li, and Changgeng, Ruan.
Detection of activated platelets using activation-specific monoclonal antibody (SZ-51) in clinical disorders.
China: N. p.,
1991.
Web.
Guoxin, Wu, Fugang, Li, Jianyong, Li, & Changgeng, Ruan.
Detection of activated platelets using activation-specific monoclonal antibody (SZ-51) in clinical disorders.
China.
Guoxin, Wu, Fugang, Li, Jianyong, Li, and Changgeng, Ruan.
1991.
"Detection of activated platelets using activation-specific monoclonal antibody (SZ-51) in clinical disorders."
China.
@misc{etde_10118893,
title = {Detection of activated platelets using activation-specific monoclonal antibody (SZ-51) in clinical disorders}
author = {Guoxin, Wu, Fugang, Li, Jianyong, Li, and Changgeng, Ruan}
abstractNote = {A direct test for activated platelets in whole blood was developed by radioimmunoassay with {sup 125}I labeled SZ-51, an antibody specific for an {alpha}-granule membrane protein (GMP-140) that associates with the platelet surface during secretion. The assay had sufficient sensitivity to detect as few as 2% activated platelets. In 50 normal subjects, minimal GMP-140 molecules per platelet were expressed on the surface of circulating platelets. Ten patients undergoing cardiopulmonary bypass had transiently increased expression of GMP-140 molecules during the bypass procedure, especially at the end of bypass. Evaluation of 18 patients with epidemic hemorrhagic fever (EHF) has shown that the number of GMP-140 molecules on the platelet surface was closely related to the four different phases of EHF. In six patients suffered from acute myocardial infarction (AMI), the number of GMP-140 molecules changed with the procession of AMI and the highest occurred 48 h after AMI. The GMP-140 molecules were also increased in patients with asthma attack (n = 14), but not in patients with idiopathic thrombocytopenic purpura (n = 11) and diabetic mellitus (n = 48). Taken together, these studies suggest that activated platelet can be reliably measured in whole blood using radiolabeled SZ-51 antibody and the detection of activated platelets is potentially useful in identifying patients with certain thrombotic disorders and others.}
place = {China}
year = {1991}
month = {Oct}
}
title = {Detection of activated platelets using activation-specific monoclonal antibody (SZ-51) in clinical disorders}
author = {Guoxin, Wu, Fugang, Li, Jianyong, Li, and Changgeng, Ruan}
abstractNote = {A direct test for activated platelets in whole blood was developed by radioimmunoassay with {sup 125}I labeled SZ-51, an antibody specific for an {alpha}-granule membrane protein (GMP-140) that associates with the platelet surface during secretion. The assay had sufficient sensitivity to detect as few as 2% activated platelets. In 50 normal subjects, minimal GMP-140 molecules per platelet were expressed on the surface of circulating platelets. Ten patients undergoing cardiopulmonary bypass had transiently increased expression of GMP-140 molecules during the bypass procedure, especially at the end of bypass. Evaluation of 18 patients with epidemic hemorrhagic fever (EHF) has shown that the number of GMP-140 molecules on the platelet surface was closely related to the four different phases of EHF. In six patients suffered from acute myocardial infarction (AMI), the number of GMP-140 molecules changed with the procession of AMI and the highest occurred 48 h after AMI. The GMP-140 molecules were also increased in patients with asthma attack (n = 14), but not in patients with idiopathic thrombocytopenic purpura (n = 11) and diabetic mellitus (n = 48). Taken together, these studies suggest that activated platelet can be reliably measured in whole blood using radiolabeled SZ-51 antibody and the detection of activated platelets is potentially useful in identifying patients with certain thrombotic disorders and others.}
place = {China}
year = {1991}
month = {Oct}
}